We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
S100A10
HPA
RESOURCES
  • TISSUE
  • BRAIN
  • SINGLE CELL
  • SUBCELLULAR
  • CANCER
  • BLOOD
  • CELL LINE
  • STRUCTURE & INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Antibody panel
Tissue
Main location
Patient ID
Annotation
Tissue
Category
Tau score
Cluster
Reliability
Brain region
Category
Tau score
Brain region
Category
Tau score
Brain region
Category
Tau score
Cluster
Reliability
Tissue
Cell type
Enrichment
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell lineage
Category
Tau score
Cluster
Cluster
Location
Searches
Location
Cell line
Class
Type
Phase
Reliability
Cancer
Prognosis
Cancer
Category
Cancer
Category
Tau score
Cluster
Variants
Interacting gene (ensg_id)
Type
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Data type
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • SUBCELL

  • CANCER

  • BLOOD

  • CELL LINE

  • STRUCT & INT

  • S100A10
CANCER PANCREATIC CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
PAAD TCGA PAAD VALIDATION PROTEIN PDAC CPTAC PROTEIN EXPRESSION
ANTIBODIES
AND
VALIDATION
Dictionary
Pancreatic cancer
Human cancer
Pancreatic adenocarcinoma
PANCREATIC ADENOCARCINOMA (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

S100A10 is potential prognostic, high expression is unfavorable in Pancreatic Adenocarcinoma (TCGA)


Stage:

Survival analysis
Current cut offi

Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.

:
Best expression cut offi

Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .

When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.

: 1410.69
Median expressioni

Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.

: N/A
Median follow up timei

Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.

: N/A
P scorei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

N/A
5-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
5-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
TCGA RNA samplesi

RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average pTPM 1452.0
Number of samples 176
Samples
Sample Description pTPM
TCGA-2J-AAB6-01A 75 years, male, white, stage:Stage IIA, dead, 293 days 4332.9
TCGA-FB-AAQ2-01A 81 years, female, white, stage:Stage IIB, dead, 153 days 3967.1
TCGA-2J-AABH-01A 61 years, male, white, stage:Stage IIA, alive, 1287 days 3965.3
TCGA-H6-8124-01A 56 years, female, white, stage:Stage IIB, alive, 392 days 3550.9
TCGA-3A-A9J0-01A 75 years, male, white, stage:Stage IIB, alive, 743 days 3419.5
TCGA-S4-A8RO-01A 75 years, female, white, stage:Stage IIB, alive, 525 days 3261.3
TCGA-YY-A8LH-01A 61 years, female, white, stage:Stage IIB, alive, 2016 days 3166.7
TCGA-RB-A7B8-01A 81 years, female, white, stage:Stage IIB, dead, 466 days 3142.8
TCGA-FB-AAPU-01A 41 years, female, asian, stage:Stage IIA, dead, 381 days 3142.0
TCGA-2J-AABU-01A 56 years, male, white, stage:Stage IIB, dead, 277 days 3027.6
TCGA-IB-AAUU-01A 35 years, male, white, stage:Stage IIB, alive, 245 days 2945.7
TCGA-IB-A6UF-01A 63 years, male, white, stage:Stage IIB, alive, 666 days 2899.6
TCGA-IB-8127-01A 59 years, male, white, stage:Stage IIB, alive, 522 days 2802.7
TCGA-HZ-A9TJ-01A 70 years, male, white, stage:Stage IV, alive, 603 days 2781.1
TCGA-HZ-8636-01A 58 years, female, white, stage:Stage IV, dead, 545 days 2730.7
TCGA-FB-AAQ0-01A 68 years, male, white, stage:Stage IIA, dead, 473 days 2728.0
TCGA-2L-AAQA-01A 76 years, male, white, stage:Stage IIB, dead, 143 days 2651.8
TCGA-2J-AAB4-01A 48 years, male, white, stage:Stage IIB, alive, 729 days 2624.0
TCGA-HZ-A8P1-01A 81 years, male, white, stage:Stage IB, alive, 7 days 2569.2
TCGA-IB-AAUN-01A 74 years, female, white, stage:Stage IB, dead, 144 days 2545.5
TCGA-2J-AABK-01A 71 years, male, white, stage:Stage IIB, alive, 484 days 2506.2
TCGA-F2-6879-01A 57 years, male, white, stage:Stage IIB, dead, 334 days 2498.4
TCGA-HZ-7919-01A 52 years, female, white, stage:Stage IIB, dead, 593 days 2497.6
TCGA-2J-AAB1-01A 65 years, male, white, stage:Stage IIB, dead, 66 days 2372.0
TCGA-2L-AAQL-01A 82 years, male, white, stage:Stage IIB, dead, 292 days 2344.1
TCGA-HV-A7OL-01A 70 years, male, asian, stage:Stage IIA, alive, 252 days 2311.2
TCGA-IB-A7LX-01A 57 years, male, white, stage:Stage IIB, dead, 250 days 2266.9
TCGA-OE-A75W-01A 75 years, male, white, stage:Stage IIA, dead, 267 days 2243.3
TCGA-HZ-7926-01A 57 years, male, black or african american, stage:Stage IIB, dead, 518 days 2226.0
TCGA-2J-AABO-01A 43 years, male, white, stage:Stage IIB, alive, 440 days 2210.2
TCGA-2J-AABE-01A 73 years, male, white, stage:Stage IIA, alive, 676 days 2180.7
TCGA-2L-AAQJ-01A 49 years, female, white, stage:Stage III, dead, 394 days 2143.3
TCGA-2J-AAB8-01A 71 years, male, white, stage:Stage IIB, alive, 80 days 2122.1
TCGA-3A-A9IH-01A 66 years, female, white, stage:Stage IA, alive, 1021 days 2109.6
TCGA-3A-A9IU-01A 65 years, male, white, stage:Stage IIB, dead, 458 days 2102.8
TCGA-IB-7885-01A 78 years, female, white, stage:Stage IIB, alive, 1257 days 2085.3
TCGA-YH-A8SY-01A 73 years, female, white, stage:'--, alive, 388 days 2074.9
TCGA-3E-AAAZ-01A 71 years, male, white, stage:Stage IIA, dead, 2182 days 2049.4
TCGA-M8-A5N4-01A 48 years, female, stage:Stage IIA, alive, 584 days 2027.0
TCGA-XD-AAUI-01A 50 years, female, white, stage:Stage IIB, dead, 366 days 1979.1
TCGA-IB-7893-01A 64 years, male, white, stage:Stage IIA, dead, 117 days 1905.3
TCGA-3A-A9IZ-01A 47 years, male, white, stage:Stage IIB, dead, 308 days 1905.2
TCGA-FB-AAQ1-01A 49 years, male, white, stage:Stage IIB, dead, 123 days 1896.9
TCGA-2J-AABF-01A 73 years, male, white, stage:Stage IIB, dead, 691 days 1885.0
TCGA-FB-A545-01A 72 years, female, white, stage:Stage IIB, dead, 732 days 1859.2
TCGA-HV-AA8X-01A 75 years, female, asian, stage:Stage IIB, dead, 532 days 1841.0
TCGA-IB-7889-01A 85 years, female, white, stage:Stage IIB, dead, 481 days 1814.1
TCGA-L1-A7W4-01A 48 years, female, white, stage:Stage IIB, dead, 278 days 1811.0
TCGA-IB-A5SQ-01A 56 years, female, white, stage:Stage IB, dead, 219 days 1794.1
TCGA-IB-7890-01A 73 years, male, stage:Stage IB, dead, 598 days 1784.3
TCGA-IB-7645-01A 44 years, female, stage:Stage IIB, dead, 1502 days 1774.7
TCGA-XN-A8T3-01A 67 years, male, white, stage:Stage IB, alive, 951 days 1756.3
TCGA-2L-AAQI-01A 66 years, male, white, stage:Stage IIB, dead, 103 days 1753.8
TCGA-HV-A5A6-01A 65 years, female, asian, stage:Stage IIB, dead, 2036 days 1677.0
TCGA-HZ-7289-01A 77 years, male, white, stage:Stage IIB, dead, 661 days 1676.8
TCGA-IB-7646-01A 60 years, male, white, stage:Stage IIB, dead, 145 days 1667.8
TCGA-IB-AAUQ-01A 50 years, male, white, stage:Stage IIB, dead, 183 days 1666.6
TCGA-RB-AA9M-01A 43 years, male, white, stage:Stage IIB, alive, 286 days 1664.5
TCGA-FB-AAQ3-01A 65 years, female, white, stage:Stage IIB, dead, 31 days 1654.3
TCGA-FB-AAPZ-01A 54 years, male, white, stage:Stage IIB, alive, 716 days 1643.0
TCGA-IB-AAUO-01A 64 years, female, white, stage:Stage IIB, dead, 239 days 1642.4
TCGA-PZ-A5RE-01A 44 years, female, white, stage:Stage IIB, dead, 470 days 1641.4
TCGA-HZ-A77O-01A 77 years, female, white, stage:Stage IIB, dead, 160 days 1628.1
TCGA-IB-7887-01A 62 years, female, white, stage:Stage IIB, dead, 110 days 1612.2
TCGA-F2-A44G-01A 79 years, female, white, stage:Stage IIB, dead, 233 days 1605.1
TCGA-FB-A78T-01A 71 years, female, white, stage:Stage IIB, dead, 375 days 1601.2
TCGA-US-A779-01A 54 years, female, white, stage:Stage IIB, dead, 511 days 1597.3
TCGA-H6-A45N-01A 88 years, female, white, stage:Stage IIB, dead, 397 days 1593.7
TCGA-HZ-A4BH-01A 75 years, male, white, stage:Stage IIB, alive, 194 days 1576.9
TCGA-FB-AAQ6-01A 85 years, male, white, stage:Stage IA, dead, 244 days 1566.9
TCGA-3A-A9IC-01A 61 years, female, white, stage:Stage IIB, dead, 738 days 1552.8
TCGA-HZ-7922-01A 61 years, female, white, stage:Stage IIB, alive, 4 days 1548.8
TCGA-US-A77G-01A 64 years, male, white, stage:Stage IIB, dead, 12 days 1534.0
TCGA-3A-A9IB-01A 69 years, female, white, stage:Stage IIB, dead, 224 days 1524.4
TCGA-3A-A9I7-01A 45 years, male, black or african american, stage:Stage IIB, alive, 1323 days 1521.5
TCGA-FB-A5VM-01A 74 years, male, white, stage:Stage IB, dead, 498 days 1520.0
TCGA-2L-AAQE-01A 56 years, male, white, stage:Stage IIB, dead, 684 days 1517.0
TCGA-HZ-A49I-01A 77 years, male, white, stage:Stage IIB, dead, 308 days 1514.5
TCGA-IB-7886-01A 80 years, male, white, stage:Stage IIB, dead, 123 days 1483.0
TCGA-FB-AAPY-01A 71 years, male, white, stage:Stage IIB, dead, 1059 days 1478.5
TCGA-FB-AAPQ-01A 65 years, male, white, stage:Stage IIB, dead, 1130 days 1473.4
TCGA-HZ-7925-01A 66 years, male, white, stage:Stage IIB, dead, 614 days 1441.8
TCGA-IB-A5SS-01A 64 years, female, white, stage:Stage IIB, dead, 460 days 1428.4
TCGA-2J-AABA-01A 55 years, male, white, stage:Stage IIB, dead, 607 days 1420.6
TCGA-HV-A5A3-01A 50 years, male, asian, stage:Stage IIA, dead, 128 days 1416.7
TCGA-YB-A89D-01A 59 years, male, white, stage:Stage IIB, alive, 350 days 1404.7
TCGA-S4-A8RM-01A 67 years, male, white, stage:Stage IIB, alive, 737 days 1334.7
TCGA-3E-AAAY-01A 67 years, male, white, stage:Stage IIB, alive, 2285 days 1322.3
TCGA-S4-A8RP-01A 77 years, female, white, stage:Stage IIB, dead, 702 days 1309.7
TCGA-FB-A7DR-01A 48 years, male, asian, stage:Stage IIA, dead, 353 days 1299.1
TCGA-XD-AAUL-01A 56 years, male, white, stage:Stage IIA, alive, 498 days 1295.2
TCGA-HZ-A77Q-01A 55 years, female, white, stage:Stage IIB, alive, 33 days 1290.6
TCGA-2J-AABI-01A 55 years, female, white, stage:Stage IIA, alive, 969 days 1277.9
TCGA-HZ-8005-01A 81 years, male, white, stage:Stage IIB, dead, 120 days 1271.0
TCGA-LB-A7SX-01A 74 years, female, black or african american, stage:Stage IIB, dead, 393 days 1264.7
TCGA-HV-A5A4-01A 72 years, female, asian, stage:Stage IIA, alive, 232 days 1244.4
TCGA-2J-AAB9-01A 70 years, female, white, stage:Stage IIB, dead, 627 days 1241.7
TCGA-Q3-AA2A-01A 64 years, female, white, stage:Stage IB, alive, 95 days 1234.2
TCGA-HZ-8315-01A 54 years, female, white, stage:Stage IIA, dead, 299 days 1196.7
TCGA-LB-A8F3-01A 64 years, female, black or african american, stage:Stage IIA, alive, 379 days 1170.1
TCGA-IB-A5ST-01A 64 years, female, white, stage:Stage IIB, alive, 635 days 1158.9
TCGA-HV-A5A5-01A 61 years, female, asian, stage:Stage IIB, alive, 289 days 1151.3
TCGA-US-A774-01A 76 years, female, white, stage:Stage IIB, dead, 695 days 1151.1
TCGA-HZ-A4BK-01A 72 years, male, white, stage:Stage IIB, alive, 657 days 1141.2
TCGA-HZ-7918-01A 72 years, male, white, stage:Stage IIB, alive, 969 days 1120.8
TCGA-IB-7644-01A 65 years, female, white, stage:Stage IV, dead, 394 days 1094.8
TCGA-3A-A9I9-01A 67 years, male, white, stage:Stage IIA, dead, 634 days 1079.1
TCGA-HZ-8001-01A 69 years, male, white, stage:Stage III, alive, 706 days 1073.6
TCGA-FB-AAPP-01A 71 years, male, white, stage:Stage IIB, dead, 485 days 1069.3
TCGA-FB-A4P5-01A 69 years, female, white, stage:Stage IIB, dead, 179 days 1052.9
TCGA-XN-A8T5-01A 53 years, female, white, stage:Stage IB, alive, 720 days 1052.5
TCGA-F2-A8YN-01A 76 years, male, white, stage:Stage IIA, alive, 517 days 1036.8
TCGA-HZ-7924-01A 60 years, female, white, stage:Stage IIA, alive, 840 days 1034.1
TCGA-HV-AA8V-01A 50 years, male, asian, stage:Stage IIB, alive, 920 days 1030.8
TCGA-HZ-A49G-01A 58 years, female, white, stage:Stage IIB, alive, 660 days 1023.1
TCGA-IB-7652-01A 49 years, female, asian, stage:Stage IIB, alive, 1116 days 1001.5
TCGA-IB-AAUV-01A 49 years, male, white, stage:Stage IIB, alive, 404 days 990.4
TCGA-IB-A6UG-01A 65 years, male, white, stage:Stage IIB, dead, 41 days 983.5
TCGA-US-A77E-01A 73 years, male, white, stage:Stage IIB, dead, 430 days 979.4
TCGA-HZ-8002-01A 61 years, male, white, stage:Stage IIB, dead, 366 days 959.5
TCGA-FB-A4P6-01A 54 years, male, white, stage:Stage IIB, alive, 767 days 958.2
TCGA-FB-AAPS-01A 62 years, female, white, stage:Stage IIB, alive, 228 days 957.8
TCGA-XD-AAUH-01A 57 years, female, white, stage:Stage IIB, alive, 395 days 951.7
TCGA-IB-A5SO-01A 71 years, male, white, stage:Stage IIB, dead, 365 days 932.4
TCGA-IB-7888-01A 66 years, female, black or african american, stage:Stage IIA, dead, 1332 days 925.6
TCGA-IB-AAUP-01A 68 years, male, white, stage:Stage IIB, alive, 431 days 914.4
TCGA-IB-AAUS-01A 84 years, female, white, stage:Stage IIB, alive, 225 days 902.2
TCGA-F2-A7TX-01A 77 years, male, white, stage:Stage IIB, dead, 95 days 881.1
TCGA-IB-7649-01A 73 years, female, stage:Stage IIB, dead, 467 days 864.2
TCGA-2J-AABR-01A 60 years, female, white, stage:Stage IIA, alive, 438 days 855.8
TCGA-XD-AAUG-01A 66 years, female, white, stage:Stage IV, alive, 420 days 848.9
TCGA-F2-7276-01A 64 years, male, white, stage:Stage IIB, dead, 216 days 840.2
TCGA-RL-AAAS-01A 60 years, female, white, stage:Stage IB, alive, 9 days 840.1
TCGA-US-A77J-01A 81 years, female, white, stage:Stage IIB, dead, 568 days 832.1
TCGA-IB-A7M4-01A 81 years, male, white, stage:Stage IIB, alive, 483 days 830.5
TCGA-IB-AAUW-01A 63 years, female, white, stage:Stage IIB, dead, 230 days 821.3
TCGA-IB-AAUR-01A 67 years, male, white, stage:Stage IIB, alive, 338 days 817.4
TCGA-Q3-A5QY-01A 58 years, male, white, stage:Stage IIB, alive, 416 days 811.3
TCGA-IB-A5SP-01A 77 years, male, white, stage:Stage IIA, alive, 482 days 802.6
TCGA-HZ-8317-01A 69 years, female, white, stage:Stage IIB, dead, 378 days 790.0
TCGA-US-A776-01A 61 years, male, white, stage:Stage IIA, alive, 1216 days 786.4
TCGA-2J-AABT-01A 72 years, female, white, stage:Stage IIB, alive, 319 days 777.9
TCGA-3A-A9I5-01A 57 years, male, white, stage:'--, alive, 1794 days 771.3
TCGA-HZ-A77P-01A 77 years, male, white, stage:Stage IIB, alive, 330 days 767.3
TCGA-IB-7651-01A 64 years, female, white, stage:Stage IIB, dead, 603 days 758.4
TCGA-H8-A6C1-01A 53 years, male, white, stage:Stage IIA, alive, 671 days 753.7
TCGA-3A-A9IX-01A 40 years, male, white, stage:Stage IA, alive, 1037 days 751.8
TCGA-IB-7891-01A 49 years, female, white, stage:Stage IIB, dead, 913 days 742.7
TCGA-IB-7654-01A 80 years, male, white, stage:Stage IIB, dead, 476 days 739.4
TCGA-Z5-AAPL-01A 74 years, female, white, stage:Stage IIA, alive, 467 days 688.7
TCGA-HZ-A49H-01A 68 years, female, white, stage:Stage IIB, alive, 491 days 646.5
TCGA-IB-7897-01A 53 years, female, white, stage:Stage IIB, dead, 486 days 640.0
TCGA-HZ-7920-01A 71 years, male, white, stage:Stage IB, dead, 236 days 636.8
TCGA-IB-AAUT-01A 65 years, male, white, stage:Stage IIB, alive, 287 days 615.4
TCGA-F2-7273-01A 54 years, male, black or african american, stage:Stage IIB, dead, 592 days 606.0
TCGA-LB-A9Q5-01A 63 years, female, white, stage:Stage IIB, dead, 313 days 601.5
TCGA-HZ-8638-01A 84 years, female, white, stage:Stage IA, dead, 151 days 596.8
TCGA-HZ-8637-01A 76 years, female, white, stage:Stage IIB, dead, 517 days 586.7
TCGA-2J-AABP-01A 58 years, female, white, stage:Stage IIB, alive, 463 days 562.4
TCGA-HZ-8519-01A 73 years, male, white, stage:Stage IA, alive, 454 days 511.7
TCGA-F2-A44H-01A 65 years, male, white, stage:Stage IIA, alive, 586 days 505.0
TCGA-HZ-7923-01A 65 years, male, white, stage:Stage IIA, alive, 314 days 489.5
TCGA-HV-A7OP-01A 72 years, male, asian, stage:Stage IIB, alive, 978 days 341.1
TCGA-2J-AABV-01A 74 years, male, white, stage:Stage IIB, dead, 652 days 332.9
TCGA-IB-AAUM-01A 76 years, male, white, stage:Stage IIB, alive, 8 days 274.1
TCGA-3A-A9IJ-01A 65 years, male, white, stage:Stage IB, alive, 1854 days 267.5
TCGA-2L-AAQM-01A 52 years, male, white, stage:Stage IIB, alive, 1383 days 245.7
TCGA-HZ-8003-01A 65 years, female, white, stage:Stage IIB, dead, 596 days 238.6
TCGA-IB-8126-01A 79 years, female, white, stage:Stage III, alive, 462 days 235.1
TCGA-3A-A9IL-01A 39 years, female, white, stage:Stage I, alive, 2741 days 195.1
TCGA-3A-A9IV-01A 59 years, female, white, stage:Stage IB, alive, 1103 days 191.7
TCGA-3A-A9IS-01A 67 years, male, white, stage:Stage IB, alive, 998 days 165.9
TCGA-3A-A9IN-01A 62 years, female, white, stage:Stage IB, alive, 2084 days 128.6
TCGA-3A-A9IO-01A 55 years, male, white, stage:'--, alive, 1942 days 98.3
TCGA-F2-6880-01A 70 years, male, white, stage:Stage IIB, alive, 295 days 60.7
TCGA-3A-A9IR-01A 64 years, female, white, stage:Stage IB, alive, 1542 days 60.6
Show allShow less
PANCREATIC ADENOCARCINOMA (VALIDATION) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

S100A10 is not prognostic in Pancreatic Adenocarcinoma (validation)


Stage:
Survival analysis
Current cut offi

Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.

:
Best expression cut offi

Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .

When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.

: 792.02
Median expressioni

Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.

: N/A
Median follow up timei

Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.

: N/A
P scorei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

N/A
5-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
5-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
TCGA RNA samplesi

RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average pTPM 668.6
Number of samples 80
Samples
Sample Description pTPM
DO33344 70 years, male, NA, stage:, dead, 361 days 1776.6
DO34616 68 years, female, NA, stage:, alive, 666 days 1633.1
DO49138 74 years, male, NA, stage:, dead, 230 days 1519.5
DO34680 75 years, male, NA, stage:, dead, 99 days 1433.8
DO49129 50 years, male, NA, stage:, alive, 337 days 1423.4
DO34448 79 years, female, NA, stage:, dead, 719 days 1313.8
DO49130 76 years, female, NA, stage:, alive, 351 days 1275.9
DO34368 64 years, female, NA, stage:, dead, 537 days 1156.2
DO49080 60 years, male, NA, stage:, alive, 83 days 1142.3
DO49178 58 years, male, NA, stage:, dead, 27 days 1122.8
DO49185 55 years, male, NA, stage:, alive, 179 days 1110.4
DO49204 67 years, male, NA, stage:, dead, 156 days 1097.8
DO49135 65 years, male, NA, stage:, alive, 270 days 966.8
DO32878 69 years, female, NA, stage:, dead, 260 days 961.9
DO34905 64 years, male, NA, stage:, alive, 1142 days 958.6
DO33368 81 years, male, NA, stage:, dead, 98 days 947.6
DO49079 50 years, male, NA, stage:, dead, 332 days 939.2
DO34728 77 years, female, NA, stage:, alive, 508 days 939.0
DO34312 58 years, female, NA, stage:, dead, 226 days 916.0
DO32863 60 years, male, NA, stage:, dead, 715 days 892.6
DO49090 77 years, female, NA, stage:, dead, 152 days 849.6
DO49172 60 years, female, NA, stage:, dead, 1021 days 849.1
DO33512 female, NA, stage:, dead, 499 days 840.2
DO34504 37 years, male, NA, stage:, dead, 257 days 792.0
DO49164 70 years, male, NA, stage:, alive, 272 days 767.1
DO33480 52 years, male, NA, stage:, alive, 1054 days 740.5
DO33408 68 years, female, NA, stage:, alive, 909 days 728.2
DO34288 83 years, female, NA, stage:, dead, 220 days 714.8
DO32860 57 years, male, NA, stage:, dead, 1259 days 706.1
DO49113 46 years, female, NA, stage:, alive, 413 days 703.1
DO49166 40 years, female, NA, stage:, alive, 222 days 695.1
DO34656 61 years, female, NA, stage:, alive, 834 days 673.3
DO49198 61 years, female, NA, stage:, dead, 251 days 659.4
DO34600 77 years, male, NA, stage:, dead, 537 days 653.7
DO34640 49 years, female, NA, stage:, dead, 287 days 645.9
DO33400 76 years, female, NA, stage:, alive, 1043 days 636.4
DO34696 75 years, male, NA, stage:, alive, 689 days 611.3
DO34736 78 years, female, NA, stage:, dead, 203 days 607.4
DO33336 67 years, female, NA, stage:, dead, 451 days 605.8
DO33472 75 years, female, NA, stage:, dead, 388 days 604.5
DO33376 62 years, female, NA, stage:, alive, 909 days 602.4
DO34809 74 years, female, NA, stage:, dead, 297 days 587.7
DO34785 67 years, female, NA, stage:, alive, 721 days 587.4
DO34849 86 years, female, NA, stage:, dead, 272 days 580.1
DO34720 68 years, male, NA, stage:, alive, 555 days 565.6
DO32875 69 years, male, NA, stage:, dead, 348 days 561.9
DO34801 60 years, male, NA, stage:, alive, 626 days 554.9
DO49193 60 years, male, NA, stage:, dead, 1 days 554.7
DO32900 51 years, male, NA, stage:, dead, 768 days 552.7
DO49183 51 years, female, NA, stage:, dead, 429 days 552.2
DO49127 77 years, female, NA, stage:, alive, 392 days 518.3
DO49074 49 years, male, NA, stage:, dead, 168 days 514.8
DO34264 63 years, female, NA, stage:, dead, 1144 days 485.7
DO49175 68 years, male, NA, stage:, dead, 414 days 474.1
DO34608 72 years, female, NA, stage:, dead, 709 days 456.9
DO34793 56 years, male, NA, stage:, dead, 427 days 451.6
DO49170 67 years, male, NA, stage:, alive, 197 days 450.1
DO33128 72 years, male, NA, stage:, dead, 423 days 422.0
DO32829 78 years, female, NA, stage:T2N0MX, dead, 1874 days 417.9
DO33392 70 years, male, NA, stage:, alive, 1014 days 394.5
DO49137 67 years, female, NA, stage:, alive, 232 days 385.9
DO49184 56 years, male, NA, stage:, dead, 455 days 384.6
DO33488 61 years, male, NA, stage:, alive, 844 days 375.7
DO34817 72 years, female, NA, stage:, alive, 540 days 369.3
DO49133 55 years, female, NA, stage:, alive, 188 days 367.3
DO49087 68 years, female, NA, stage:, dead, 260 days 355.8
DO49168 58 years, male, NA, stage:, alive, 149 days 335.7
DO49181 77 years, male, NA, stage:, dead, 1534 days 322.6
DO49078 79 years, male, NA, stage:, dead, 465 days 302.7
DO33552 70 years, female, NA, stage:, alive, 873 days 295.4
DO34240 72 years, male, NA, stage:, dead, 236 days 285.0
DO49199 52 years, male, NA, stage:, dead, 1095 days 269.6
DO33600 77 years, female, NA, stage:, alive, 854 days 262.7
DO33984 64 years, male, NA, stage:, alive, 847 days 261.2
DO49076 64 years, male, NA, stage:, dead, 480 days 255.2
DO33544 83 years, female, NA, stage:, dead, 412 days 229.3
DO34432 82 years, female, NA, stage:, dead, 400 days 226.4
DO34961 71 years, male, NA, stage:, dead, 632 days 168.9
DO33168 80 years, female, NA, stage:, dead, 8 days 133.2
DO34336 70 years, female, NA, stage:, alive, 743 days 11.7
Show allShow less
PANCREATIC DUCTAL ADENOCARCINOMA - Protein relative expression (CPTAC)
Number of samples 235
Samples
Sample ID Sample type nRPX
CPT0088320003 Tumor 0.8
CPT0124500004 Tumor 0.7
WU-PDA1 Tumor 0.6
CPT0078090004 Tumor 0.6
CPT0063570003 Tumor 0.5
CPT0081060004 Tumor 0.5
CPT0247040003 Tumor 0.5
CPT0124610004 Tumor 0.4
CPT0187930005 Tumor 0.4
CPT0209640005 Tumor 0.4
CPT0077860003 Tumor 0.4
CPT0019410004 Tumor 0.4
CPT0086190004 Tumor 0.4
CPT0001750003 Normal 0.4
CPT0235230004 Tumor 0.4
CPT0019300004 Tumor 0.4
CPT0001730017 Tumor 0.4
CPT0094630004 Tumor 0.4
CPT0091660003 Tumor 0.3
CPT0064520004 Tumor 0.3
CPT0089720003 Tumor 0.3
CPT0237910004 Tumor 0.3
CPT0064090003 Tumor 0.3
CPT0081360004 Tumor 0.3
CPT0276010003 Tumor 0.3
CPT0125130003 Tumor 0.3
CPT0123990003 Tumor 0.3
CPT0064110003 Normal 0.3
CPT0126160004 Tumor 0.3
CPT0064570003 Normal 0.3
CPT0161990005 Tumor 0.3
CPT0124360003 Tumor 0.3
CPT0236340004 Tumor 0.3
CPT0226650004 Tumor 0.3
CPT0065640003 Tumor 0.3
CPT0238040005 Tumor 0.2
CPT0066020003 Normal 0.2
CPT0109200004 Tumor 0.2
CPT0226570004 Tumor 0.2
CPT0123440003 Tumor 0.2
CPT0238820005 Tumor 0.2
CPT0094230004 Tumor 0.2
CPT0081470004 Tumor 0.2
CPT0138990003 Normal 0.2
CPT0355180003 Normal 0.2
CPT0123750003 Tumor 0.1
CPT0187550004 Tumor 0.1
CPT0092630003 Tumor 0.1
CPT0124530003 Normal 0.1
CPT0246990003 Tumor 0.1
CPT0246840003 Tumor 0.1
CPT0077930004 Tumor 0.1
CPT0161770004 Tumor 0.1
CPT0238610009 Tumor 0.1
CPT0083270003 Tumor 0.1
CPT0094180003 Tumor 0.1
CPT0218200004 Tumor 0.1
CPT0226760004 Tumor 0.1
CPT0237840004 Tumor 0.1
CPT0124410004 Tumor 0.1
CPT0077880003 Normal 0.1
CPT0063970004 Tumor 0.1
CPT0078030003 Normal 0.1
CPT0226490004 Tumor 0.1
CPT0254680003 Tumor 0.1
CPT0208690004 Tumor 0.1
CPT0217700004 Tumor 0.0
CPT0238710004 Tumor 0.0
CPT0094030003 Tumor 0.0
CPT0093980004 Tumor 0.0
CPT0264150003 Tumor 0.0
CPT0088180004 Tumor 0.0
CPT0094740004 Tumor 0.0
CPT0139000004 Tumor 0.0
CPT0123860003 Tumor 0.0
CPT0208840004 Tumor 0.0
CPT0170240004 Tumor 0.0
CPT0077790004 Tumor 0.0
CPT0198700005 Tumor 0.0
C3L-00401-04 Normal 0.0
CPT0109300004 Tumor 0.0
CPT0239100009 Tumor -0.1
CPT0241320005 Tumor -0.1
CPT0065570003 Tumor -0.1
CPT0166760004 Tumor -0.1
CPT0078160004 Tumor -0.1
CPT0248410004 Tumor -0.1
CPT0226610004 Normal -0.1
CPT0093930004 Tumor -0.1
CPT0207780004 Tumor -0.1
CPT0014040003 Tumor -0.1
CPT0238530005 Tumor -0.1
CPT0011520003 Tumor -0.1
CPT0247000003 Normal -0.1
CPT0246260004 Tumor -0.1
CPT0246940003 Tumor -0.1
CPT0183450005 Tumor -0.1
CPT0248620003 Normal -0.1
CPT0209310004 Tumor -0.1
CPT0224460004 Tumor -0.1
CPT0125010003 Normal -0.1
CPT0000250017 Tumor -0.2
CPT0236700005 Tumor -0.2
CPT0208550005 Tumor -0.2
CPT0078000003 Tumor -0.2
CPT0008800003 Tumor -0.2
CPT0239910004 Tumor -0.2
CPT0008750003 Tumor -0.2
CPT0078250003 Tumor -0.2
CPT0197420004 Tumor -0.2
CPT0237270005 Tumor -0.2
CPT0238440005 Tumor -0.2
CPT0241510004 Normal -0.2
CPT0017040004 Tumor -0.2
CPT0246810003 Tumor -0.2
CPT0186040004 Tumor -0.2
CPT0227930004 Tumor -0.2
CPT0094130004 Tumor -0.2
CPT0088260004 Tumor -0.2
CPT0221240004 Tumor -0.2
CPT0124980004 Tumor -0.2
CPT0162760003 Tumor -0.2
CPT0248590004 Tumor -0.2
CPT0108400003 Tumor -0.2
CPT0197440004 Normal -0.3
CPT0086210003 Normal -0.3
CPT0183750005 Tumor -0.3
CPT0185920004 Tumor -0.3
CPT0226600004 Tumor -0.3
CPT0162660004 Tumor -0.3
CPT0226680005 Tumor -0.3
CPT0081260004 Tumor -0.3
CPT0236560004 Tumor -0.3
CPT0236780005 Tumor -0.3
CPT0207980005 Tumor -0.4
CPT0108930003 Tumor -0.4
CPT0226530004 Tumor -0.4
CPT0123650003 Tumor -0.4
CPT0236360004 Normal -0.4
CPT0174800003 Normal -0.4
CPT0094940004 Tumor -0.4
CPT0025750003 Tumor -0.4
CPT0203850004 Tumor -0.4
CPT0127270003 Tumor -0.4
CPT0238920004 Tumor -0.4
CPT0207990004 Normal -0.4
CPT0247090003 Tumor -0.5
C3L-03632-04 Normal -0.5
CPT0108960003 Normal -0.5
CPT0109010004 Tumor -0.5
CPT0246950003 Normal -0.5
CPT0221470005 Tumor -0.5
CPT0246720003 Tumor -0.5
CPT0198420004 Tumor -0.5
CPT0093860003 Tumor -0.5
CPT0276030003 Normal -0.6
CPT0198910005 Tumor -0.6
CPT0246210004 Tumor -0.6
CPT0011540003 Normal -0.6
CPT0123890003 Normal -0.6
CPT0236710004 Normal -0.6
CPT0017130003 Normal -0.6
CPT0077950003 Normal -0.6
CPT0241500004 Tumor -0.6
CPT0093880003 Normal -0.6
CPT0174700004 Tumor -0.6
CPT0025760003 Normal -0.6
CPT0162780004 Normal -0.7
CPT0162670004 Normal -0.7
CPT0125090003 Tumor -0.7
CPT0123770003 Normal -0.7
CPT0166780004 Normal -0.7
CPT0218220004 Normal -0.7
CPT0124000003 Normal -0.7
CPT0077810003 Normal -0.7
CPT0239920004 Normal -0.7
CPT0347850002 Normal -0.7
CPT0078180003 Normal -0.8
CPT0123460003 Normal -0.8
C3N-00709-06 Normal -0.8
C3N-02573-03 Normal -0.8
CPT0221250004 Normal -0.8
CPT0170260004 Normal -0.8
C3L-00189-04 Normal -0.8
KoreanReference3 Tumor -0.9
CPT0347760002 Normal -0.9
CPT0248440003 Normal -0.9
CPT0123670003 Normal -0.9
CPT0238640004 Normal -0.9
CPT0089750004 Normal -0.9
CPT0087890004 Tumor -0.9
CPT0063580003 Normal -0.9
CPT0091680003 Normal -1.0
CPT0237850004 Normal -1.0
CPT0198440004 Normal -1.0
CPT0347820002 Normal -1.0
CPT0238740004 Normal -1.0
CPT0239140004 Normal -1.0
CPT0347790002 Normal -1.0
CPT0208710004 Normal -1.0
CPT0246220004 Normal -1.0
CPT0355200003 Normal -1.0
CPT0209650004 Normal -1.1
CPT0236800004 Normal -1.1
CPT0127290003 Normal -1.1
CPT0237920004 Normal -1.1
CPT0355190003 Normal -1.1
KoreanReference1 Tumor -1.1
KoreanReference2 Tumor -1.1
CPT0198930003 Normal -1.1
CPT0208850004 Normal -1.2
CPT0347880002 Normal -1.2
CPT0187540004 Normal -1.2
CPT0183770004 Normal -1.2
CPT0238940004 Normal -1.8
CPT0247050003 Normal N/A
CPT0108410003 Normal N/A
CPT0248320003 Normal N/A
CPT0166650006 Tumor N/A
CPT0224470004 Normal N/A
C3L-01687-04 Normal N/A
CPT0138890003 Normal N/A
CPT0109110004 Tumor N/A
WU-pooled sample Tumor N/A
CPT0014060003 Normal N/A
CPT0109130003 Normal N/A
CPT0138900004 Tumor N/A
CPT0166680004 Normal N/A
CPT0094760003 Normal N/A
CPT0186050004 Normal N/A
CPT0237290004 Normal N/A
CPT0264180003 Normal N/A
CPT0063990003 Normal N/A
CPT0126200003 Normal N/A
CPT0198730004 Normal N/A
Show allShow less
PANCREATIC CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA003340

Antibody CAB025484
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Adenocarcinoma, NOS

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org